1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Prostate cancer

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Technology appraisal guidance [TA660] Published: 25 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 142 KB 25 November 2020  
  • Register of interests MSWord 41 KB 18 May 2021  

Final draft guidance: 1

  • Final draft guidance: 1  
  • Final appraisal document PDF 252 KB 23 October 2020  
  • Committee papers PDF 4.47 MB 23 October 2020  
  • Public committee slides PDF 1.12 MB 23 October 2020  

Invitation to participate

  • Final scope PDF 210 KB 17 January 2020  
  • Final stakeholder list PDF 189 KB 27 January 2020  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 245 KB 27 January 2020  
  • Equality impact assessment (Scoping) PDF 123 KB 27 January 2020  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope post referral PDF 242 KB 01 May 2019  
  • Draft matrix post referral PDF 188 KB 01 May 2019